Aurinia Pharmaceuticals (AUPH): EOP2 Meeting Results Were Better Than Could Have Been Hoped For - HC Wainwright

H.C. Wainwright analyst, Ed Arce, reiterated his Buy rating on Aurinia Pharmaceuticals (NASDAQ: AUPH) noting the FDA intends to permit a single Phase 3 trial in support of a voclosporin NDA for LN.

The analyst views this as a major win for Aurinia, especially after much investor consternation over the number of deaths at the 6- month primary readout of the Phase 2b AURA-LV trial, the results of the end-of-Phase 2 (EOP2) meeting with the FDA (announced Nov. 2) not only fully validate the company's view of that study's robustly positive results, but also provide for some unexpected elements to the Phase 3 protocol that may have the effect of further mitigating the risk of achieving a positive pivotal readout.

For an analyst ratings summary and ratings history on Aurinia Pharmaceuticals click here. For more ratings news on Aurinia Pharmaceuticals click here.

Shares of Aurinia Pharmaceuticals closed at $2.70 yesterday.

You May Also Be Interested In

• Oculis Holding AG (OCS) PT Lowered to $28 at H.C. Wainwright
• AGNC Investment Corp (AGNC) PT Lowered to $9.50 at BofA Securities
• Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'